Back to results
US 10,323,095 B2Granted
Antibody-fynomer conjugates
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsRoland Newman, Steve Granger, Michael Lyman, Dragan Grabulovski, Richard Woods, Michela Silacci, Wenjuan Zha, Isabella Attinger-Toller
Life of this patent
Estimating the term…
Abstract
Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
Claims20
A bi-specific fusion polypeptide comprising:
- (a) a fynomer sequence comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from:
- SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 1, SEQ ID NO:
- 4 and SEQ ID NO:
- 7, wherein the amino acid sequences at positions 12-17 and 31-36 of the selected fynomer sequence is maintained and the fynomer sequence binds to interleukin-17a (IL-17a);
- and
- (b) an antibody or a subsequence thereof that binds to interleukin-6 receptor (IL-6R), wherein the fynomer sequence is conjugated to the antibody, or subsequence thereof, and the fusion polypeptide binds to both IL-17a and IL-6R and inhibits both IL-17a and IL-6R activities.
8 more elements
Dependencies are inferred from the claim text.